Eltrombopag
A Phase II Study of Eltrombopag as a Novel Therapeutic Approach for Patients With Low-risk Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML) With TET2 Mutations
More Information
- Trial Status
- Not yet accepting
- Trial Phase
- Phase 2
- Enrollment
- 25 patients (estimated)
- Sponsors
- Case Comprehensive Cancer Center
- Tags
- Thrombopoietin Receptor Agonist (TPO-RA), White Blood Cell Stimulant
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 2016
- NCT Identifier
- NCT06630221
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print this trial to share with your doctor.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.